Overview
The overall goal of the randomized control trial (RCT) will be to evaluate the efficacy of modifications to a web-based tool for patient decision-making regarding return of genomic results that will more closely focus on rare cancers. Participants will be given access to a web-based decision aid (or a standard control) that guides participants in making decisions about what type of genomic results they would like to receive from testing performed in the PE-CGS study (NCT06340646).
Eligibility
Eligibility Criteria:
- Enrolled in the WU-PE-CGS study (IRB#202106129); that eligibility entails:
- Diagnosis of cholangiocarcinoma
- Diagnosis of multiple myeloma, must be African American
- Diagnosis of colorectal cancer, must be African American and age 65 or older at time of diagnosis
- At least 18 years old.
- Able to understand an IRB-approved informed consent document and agree to participation
- Have access to a personal computer, tablet or mobile device